Parabrahma Research Center with life guarantee for Covid-19 patients.
Bangalore: The Parabrahma Ayurveda Research Center has come up with a drug that has the potential to destroy all viruses in the face of concerns over the spread of Covid-19. The Parabrahma Research Center Chairman claims that this drug, which can be used by people of any age, has been given to many Covid-19 positive patients and they have recovered quickly. At the same time, he said, they want to advertise only after ensuring the success of the drug by giving it to a thousand patients. When millions of people are afflicted with the disease, it is common to complain that they are not getting the medicine they need. However, the Center claims that the single Medicine Treatment (Ottamooli – Drug) will be able to cure the disease in India within three months. They claim the drug is over a hundred years old.
The research center also plans to seek the support of foreign countries if India’s support is not forthcoming. At the same time, they say that the doctors in the medical college are supporting them. A spokesman for the research center said in a statement that it had a report that patients had been negative for two days after being given the drug, but that the Indian Medical Association and the government were prepared to publish details and video footage of patients if they were assured that no action would be taken against the doctors who provided support. They also confirm that the research center is functioning with all the documents. The e-mail was sent to the Prime Minister and the Minister of AYUSH several times but no reply was received.
Parabrahma Ayurveda Hospital is an institution that employs over 58 traditional healers and many Ayurvedic doctors. The hospital has branches in Thiruvananthapuram, Kollam, Alappuzha, Thrissur and Bangalore.
More than 100 Covid positive patients have been cured so far. They claim that using this drug not only increases immunity power but also completely destroys the virus and prevents future viral infections.